Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide versus insulin glargine in type 2 diabetes with moderate or severe chronic kidney disease
2012-000829-44Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2012
- Modality
- Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Dulaglutide with Insulin glargine (2 arms). Primary endpoint: Change from baseline in HbA1c at 26 weeks. Started Jul 2012; status: completed.
02
Drugs
dulaglutideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2012-000829-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000829-44.